Steven Paul, M.D. is a notable figure in the biotech world, particularly recognized for his role as CEO of Voyager Therapeutics from 2015 until 2018. With a solid educational background including an M.D. from an accredited medical school, Dr. Paul...

Steven Paul, M.D. is a notable figure in the biotech world, particularly recognized for his role as CEO of Voyager Therapeutics from 2015 until 2018. With a solid educational background including an M.D. from an accredited medical school, Dr. Paul switched gears from being a doctor to climbing the corporate ladder in pharmaceutical companies. He has significant experience previously working at Eli Lilly, where he held various key positions including Executive Vice President and President of Lilly Research Laboratories. Beyond his corporate roles, he was a Scientific Director at the National Institute of Mental Health, which highlights his strong foundation in neuroscience. After his time at Voyager, he transitioned to an executive science advisor role, continuing to be part of the board as a member of the Science & Technology Committee. His experience connects well with investors and the medical community, making him a prominent figure in advancing biotech solutions. Notably, his compensation fluctuated from around $673K in 2016 to just over $404K in 2018 as he shifted away from daily operations, which underscores a dynamic career path.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Voyager Therapeutics, Inc. CEOs

V

Steven Paul, M.D.

Ex-CEO of Voyager Therapeutics, Inc.

Education

B.A. in Biology and Psychology from Tulane University, M.S. and M.D. from Tulane University School of Medicine

Field of Expertise

Healthcare & Life Sciences - Medicine

Sector of Economy

Healthcare

Born

January 1, 1951 - 74 years ago

CEO of Voyager Therapeutics, Inc. for

3 years 10 months (Sep 2014 - Jul 2018)

Previous Experience

Executive Vice President, President of Lilly Research Laboratories at Eli Lilly and Company

Rivals

Competitors/colleagues of Steven Paul, M.D.

Holdings

See how much did Steven Paul, M.D. make over time.

At one point, Dr. Paul held a considerable wealth in Voyager Therapeutics shares, reflecting his strong beliefs in the company's future. His holdings reached over $1.13 million in Voyager stock during 2018 but saw fluctuations as he began to divest...

At one point, Dr. Paul held a considerable wealth in Voyager Therapeutics shares, reflecting his strong beliefs in the company's future. His holdings reached over $1.13 million in Voyager stock during 2018 but saw fluctuations as he began to divest after announcing his transition to an advisory role. In April 2018, he maintained about 1.13% ownership of the company, while in the subsequent years from late 2019, his holdings have reduced significantly as the stock price volatility led to various transactions. Most recently, his wealth in holdings has seen shifts, with values ranging from about $34.00 million to $41.30 million in 2024. This transition reflects not just personal strategy but also the company’s broader market movements.

Mar 18, 2025

A

shares

ALNY @ $244.30

B

shares

BFAM @ $127.17

S

shares

SAGE @ $NaN

Total Stock Sold

$45.47M

BFAM

$1.08M

20,000 BFAM shares

SAGE

$35.77M

282,043 SAGE shares

ALNY

$8.62M

60,000 ALNY shares

What if they kept their stock?

If Steven Paul, M.D. didn't sell their stock, today they would have:
Extra BFAM20,000 shares worth $2.73M and SAGE282,043 shares worth $10.21M and ALNY60,000 shares worth $7.66M.
This is -54.7% and $24.87M less than what they got when they sold the stock.

Charitable Transactions

SAGE

614,115 shares

SAGE

Recent Charitable Transactions

SAGE

122,400 shares

SAGE

Feb 25, 2019

Charity

SAGE

241,695 shares

SAGE

Feb 15, 2019

Charity

SAGE

244,939 shares

SAGE

Dec 31, 2018

Charity

SAGE

5,081 shares

SAGE

Feb 23, 2016

Charity

Insider Trading

See recent insider trades of Steven Paul, M.D..

ALNY

$2.59M

ALNY at $172.80/share

Apr 1, 2022

Sale

ALNY

$2.10M

ALNY at $140.00/share

Dec 18, 2020

Sale

ALNY

$3.90M

ALNY at $130.00/share

Feb 10, 2020

Sale

SAGE

$1.27M

SAGE at $161.04/share

Mar 21, 2019

Sale

SAGE

$9.74M

SAGE at $161.17/share

Mar 18, 2019

Sale

SAGE

$418.60K

SAGE at $161.00/share

Mar 1, 2019

Sale

SAGE

$322.00K

SAGE at $161.00/share

Feb 25, 2019

Sale

SAGE

122,400 shares

SAGE

Feb 25, 2019

Charity

SAGE

122,400 shares

SAGE

Feb 25, 2019

Charity

SAGE

$8.23M

SAGE at $161.38/share

Feb 15, 2019

Sale

Compensation History

See how much did Steven Paul, M.D. make over time.

Dr. Steven Paul's compensation during his time as CEO of Voyager Therapeutics varied each year. In 2016, he earned about $673K, which included a significant bonus for meeting corporate goals. His pay was structured to attract and retain talent while aligning with the company's performance. As his role transitioned to executive science advisor, his total compensation dropped to around $404K in 2018. This reduction included a notable shift away from performance-based bonuses, as his responsibilities changed from day-to-day management to more of an advisory role. His earlier years reflect typical executive compensation metrics, focusing on salary, bonuses, and the incentives tied to stock options, illustrating the common practices in biotech leadership.

Year

2018

Total Compensation

$404.75K

Salary

$298.29K

Board Justification

The compensation philosophy is designed to attract and retain talented executives while aligning their incentives with the company's performance and long-term shareholder interests.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2018 as he transitioned to a non-employee director role.

Other

$106.45K

Board Justification

This includes reimbursement of business or economy round trip tickets to and from Dr. Paul's principal residence in Indiana annually, as well as consulting services paid pursuant to his consulting agreement with the company after his transition from CEO.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was vested in 2018 as all stock options were granted in previous years and not vested in 2018.

Performance Metrics

Performance metrics for 2018 were based on corporate goals achieved at a rate of 105%.

Other Voyager Therapeutics, Inc. CEOs

Here are other CEOs of Voyager Therapeutics, Inc.

G. Andre Turenne

CEO of Voyager Therapeutics, Inc.

July 2018 - Present